ScholarGate
Асистент

Сравнение на методи

Прегледайте избраните методи един до друг; редовете с разлики са откроени.

Cancer Worry Scale×EORTC QLQ-LC13: Качество на живот при рак на белия дроб×
ОбластОнкологияОнкология
СемействоProcess / pipelineProcess / pipeline
Година на възникване19911994
СъздателLerman, C., et al.Bergman, B., et al. (EORTC Quality of Life Group)
ТипSelf-report questionnaireSelf-report questionnaire
Основополагащ източникLerman, C., Trock, B., Rimer, B. K., Jepson, C., Brody, D., & Boyce, A. (1991). Psychological side effects of breast cancer screening. Health Psychol, 10(1), 259–267. DOI ↗Bergman, B., Aaronson, N. K., Ahmedzai, S., Kaasa, S., & Sullivan, M. (1994). The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur J Cancer, 30A(5), 635–642. DOI ↗
Други названияCWSQLQ-LC13
Свързани55
РезюмеThe Cancer Worry Scale (CWS) is a brief 8-item instrument assessing the degree to which cancer-related worry interferes with daily functioning and emotional well-being. Developed by Lerman et al. in 1991, it quantifies cancer-related anxiety and distress—psychological burden distinct from symptom burden and functional impairment. It is widely used in cancer screening, treatment, and survivorship contexts to identify patients requiring psychological support.The EORTC QLQ-LC13 is a 13-item lung-cancer-specific module designed to complement the 30-item EORTC QLQ-C30 core questionnaire. Developed and validated by Bergman et al. in 1994, it measures lung-specific symptoms (dyspnea, cough, hemoptysis, chest pain) and treatment toxicities (sore mouth, dysphagia). It is the standard lung cancer-specific QoL instrument in European and international trials.
ScholarGateНабор от данни
  1. v1
  2. 1 Източници
  3. PUBLISHED
  1. v1
  2. 2 Източници
  3. PUBLISHED

Към търсенето Изтегляне на слайдове

ScholarGateСравнение на методи: Cancer Worry Scale · EORTC QLQ-LC13. Извлечено на 2026-06-20 от https://scholargate.app/bg/compare